Sysmex Corporation (FRA:0YX)

Market Cap	6.25B -8.5%
Revenue (ttm)	2.83B +4.5%
Net Income	213.22M -16.1%
EPS	0.34 -15.7%
Shares Out	n/a
PE Ratio	29.32
Forward PE	n/a
Dividend	0.21 (2.18%)
Ex-Dividend Date	Sep 29, 2026

Volume	n/a
Open	9.83
Previous Close	9.89
Day's Range	9.83 - 9.83
52-Week Range	6.51 - 11.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. T...

• Industry: Laboratory Analytical Instruments
• Founded: 1968
• Employees: 10,861
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0YX

Financial Performance

In fiscal year 2026, Sysmex's revenue was 500.01 billion, a decrease of -1.70% compared to the previous year's 508.64 billion. Earnings were 35.46 billion, a decrease of -33.93%.

Financial numbers in JPY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 20, 2026

Data Sources Report a data error